Randomized, Embedded, Multifactorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP – CAP)
This study will use a study design known as a REMAP: a Randomised, Embedded, Multifactorial, Adaptive Platform trial. The broad objective of this REMAP is, over time, to determine and continuously update the optimal set of treatments for community-acquired pneumonia in a traditional clinical trial. Selected patients are allocated to receive one treatment from a short list of alternatives (typically one or two). Different questions are tested sequentially. Patients who are eligible for participation in REMAP – CAP will be randomised to receive one intervention in each of one or more categories of treatment (“domains”). These interventions can be tested simultaneously. This trial is being ran under the direction of Beacon Hospital ICU Intensivist Dr Daniel Collins.
Further information can be found here: https://www.remapcap.org/
Short PeRiod IncideNce sTudy of Severe Acute Respiratory Infection “SPRINT – SARI”
SPRINT – SARI is an international, multi-centre, prospective, short period incidence observational study of patients in participating hospitals and intensive care units (ICUs) with severe acute respiratory infection (SARI). The primary aim of this study is to establish a research response capability for a future epidemic / pandemic through a global SARI observational study. The secondary aim of this study is to investigate the descriptive epidemiology and microbiology profiles of patients with SARI. The tertiary aim of this study is to assess the Ethics, Administrative, Regulatory and Logistic (EARL) barriers to conducting pandemic research on a global level. Further information can be found here: https://isaric.tghn.org/sprint-sari/